[Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432].
Using the Su-PS skin test, an attempt was made to evaluate whether or not this reaction could become a useful immune parameter in patients with gastrointestinal cancer. The conclusions were as follows: Late-stage patients with gastric cancer showed a weak response in the Su-PS skin test when examined preoperatively. The skin reaction to Su-PS was shown to become stronger than in the PPD and PHA test when patients received OK-432 treatment. Patients with advanced cancer having longer survival (more than 7 months) showed stronger response in the Su-PS skin test that patients having short survival (less than 6 months). It was suggested that the Su-PS skin test was useful for evaluating the immune response to OK-432 treatment.
D001688:Biological Products / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000276:immunology*; D004938:Esophageal Neoplasms / Q000276:immunology; D006801:Humans; D007428:Intradermal Tests; D010190:Pancreatic Neoplasms / Q000276:immunology; D010835:Phytohemagglutinins / Q000494:pharmacology; D010844:Picibanil / Q000627:therapeutic use*; D011135:Polysaccharides, Bacterial / Q000276:immunology; D012882:Skin Tests; D013274:Stomach Neoplasms / Q000276:immunology*; D014374:Tuberculin Test
D001688:Biological Products; D010835:Phytohemagglutinins; D011135:Polysaccharides, Bacterial; D010844:Picibanil